Preview

Rational Pharmacotherapy in Cardiology

Advanced search

MONITORING OF THE EFFICACY AND SAFETY OF HIGH-DOSE ATORVASTATIN IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

https://doi.org/10.20996/1819-6446-2018-14-2-190-196

Full Text:

Abstract

Aim. To study the effectiveness of achievement of lipid profile target levels and safety of therapy with atorvastatin in different doses in patients with acute ST-segment elevation myocardial infarction (STEMI).

Material and methods. The open prospective controlled single-center study included 90 patients with STEMI aged 32 to 65 years. In the first 24-96 hours from the disease onset the patients were randomized into two groups: the first group included 43 patients who received high-dose statin therapy – atorvastatin 80 mg/day (Group 1), the second group (Group 2) – 47 patients receiving atorvastatin 20 mg/day. Examination of patients with STEMI included the assessment of plasma lipid profile, blood levels of hepatic transaminases, creatine phosphokinase (CPK), C-reactive protein (CRP), brain natriuretic peptide (BNP), creatinine, glucose and glomerular filtration rate calculation.

Results. A decrease in the level of low density cholesterol (LDC) by 52.4% (p<0.001) was found after 24 weeks in Group 1. Achieving the target LDC level was found in 46% of patients and a decrease of LDC>50% from the baseline – in another 26%. LDC decreased by 33% in Group 2 (p<0.001). Achieving the target LDC level was found in 17% and a decrease of LDC>50% – in 15% of patients. After 24 weeks, a statistically significant decrease in hepatic transaminase activity was found in the both groups in comparison with the baseline level. The level of CRP decreased 9.1 times (p<0.001) in Group 1, and 7.8 times (p<0.001) – in Group 2. Reduction in the level of BNP was also found in Group 1 by 60% (p=0.005), and in Group 2 – by 33.8% (p<0.001). The levels of CPK, creatinine and GFR in the both groups did not change. A comparable decrease in fasting glycemia was found after 24 weeks in the both groups.

Conclusion. The revealed lipid-lowering and pleiotropic effects confirm the necessity of using atorvastatin 80 mg. The absence of changes in the level of transaminases, CPK, serious adverse effects indicates the safety of the use of high-dose statin therapy in STEMI patients for the secondary prevention of cardiovascular events.

About the Authors

L. I. Salyamova
Penza State University
Russian Federation

Lyudmila I. Salyamova – MD, PhD, Associate Professor, Chair of Therapy

Krasnaya ul. 40, Penza, 440026



S. S. Fadeeva
Penza State University
Russian Federation

Svetlana S. Fadeeva – MD, PhD, Associate Professor, Chair of Therapy

Krasnaya ul. 40, Penza, 440026



A. V. Golubeva
Penza State University
Russian Federation

Alyona V. Golubeva – MD, Postgraduate Student, Chair of Therapy

Krasnaya ul. 40, Penza, 440026



Yu. A. Tomashevskaya
Penza State University
Russian Federation

Yuliya A. Tomashevskaya – MD, PhD, Associate Professor, Chair of Therapy

Krasnaya ul. 40, Penza, 440026

 

 

 



V. E. Oleynikov
Penza State University
Russian Federation

Valentin E. Oleynikov – MD, PhD, Professor, Head of Chair of Therapy

Krasnaya ul. 40, Penza, 440026



References

1. WHO, World Heart Federation, World Stroke Organization. Global Atlas on cardiovascular disease prevention and control. Zheneva: WHO; 2013.

2. Diagnosis and correction of lipid metabolism disorders prevention and treatment of atherosclerosis. Russian recommendations (V revision). Atherosclerosis and Dyslipidemia. 2012;4:5-52. (In Russ.)

3. Rojer V.L., Go A.S., Lloyd-Jones D.M., et. al. Heart disease and stroke statistics-2012 update: A Report From the American Heart Association. Circulation. 2012;125(1):e2-e220. doi: 10.1161/CIR.0b013e31823ac046.

4. Koren M.J., Hunninghake D.B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44(9):1772-9. doi: 10.1016/j.jacc.2004.07.053.

5. Aronov D. M., Bubnova M. G. Pleiotropic effects of statins at the present stage of their study (focus on atorvastatin). Part I. CardioSomatika. 2012;3:55-64. (In Russ.)

6. Diagnosis and correction of lipid metabolism disorders prevention and treatment of atherosclerosis. Russian recommendations (VI revision). Atherosclerosis and Dyslipidemia. 2017;3:5-22. (In Russ.)

7. Boytsov S. A., Susekov, A. V., Aronov D. M., et al. Topical issues of statin therapy in clinical practice. The meeting of the Council of experts. Atherosclerosis and Dyslipidemia. 2011;1:67-9. (In Russ.)

8. Oganov R.G., Kukharchuk V.V., Arutyunov G.P. et al. (on behalf of the researchers DYSIS). Persistent violations of lipid spectrum in patients with dyslipidemia receiving statins in clinical practice in the Russian Federation (the Russian part of the study DYSIS). Cardiovascular Therapy and Prevention. 2012;11(4):70-8. (In Russ.)

9. Ruda M. Ya., O. V. Averkov, et al. Diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation of the electrocardiogram. Cardiology Bulletin. 2014;4:3-60. (In Russ.)

10. Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi: 10.1016/S01406736(10)61350-5.

11. Jones P.H., Hunninghake D.B., Ferdinand K.C. et al. Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388-99. doi: 10.1016/j.clinthera.2004.09.006.

12. Sadeghi R., Asadpour-Piranfar M., Asadollahi M., et al. The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident. ARYA Atheroscler. 2014;10(6):298-304.

13. Oleynikov V. E., Matrosova I. B., Melnikova E. A. the Dynamics of indices of vascular stiffness and lipid metabolism in patients with ischemic heart disease on the background of treatment with high doses of atorvastatin. Atherosclerosis and Dyslipidemia. 2013;3(12):17-24. (In Russ.)

14. Drapkina O. M., Ashihmin Ya. I. Acute coronary syndrome. When to prescribe statins? Atherosclerosis and Dyslipidemia. 2011;3:40-4. (In Russ.)

15. Aronov D. M. Pleiotropic effects of statins at the present stage of their study: focus on atorvastatin. Part III. Mechanisms of pleiotropy of statins. CardioSomatika. 2013; 2: 20-6. (In Russ.)

16. Bonnet J., McPherson R., Tedgui A., et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

17. Kumar A., Cannon C.P. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 2009;84(10):917-38.

18. Liu H.L., Yang Y., Yang S.L. Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study. Clin Ther. 2013;35(3):261-72. doi: 10.1016/j.clinthera.2013.01.009.

19. Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123-30. doi: 10.1016/j.amjcard.2012.12.037.

20. Erqou S., Lee C.C., Adler A.I. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57(12):2444-52. doi: 10.1007/s00125-0143374-x.

21. Barbarash O. L., Gruzdeva O. V., Akbasheva O. E. et al. Clinical and biochemical predictors of the manifestation of diabetes mellitus after myocardial infarction. Russian Journal of Cardiology. 2014;3(107):87-94. (In Russ.)


For citation:


Salyamova L.I., Fadeeva S.S., Golubeva A.V., Tomashevskaya Y.A., Oleynikov V.E. MONITORING OF THE EFFICACY AND SAFETY OF HIGH-DOSE ATORVASTATIN IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. Rational Pharmacotherapy in Cardiology. 2018;14(2):190-196. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-2-190-196

Views: 200


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)